EFECTOS ADVERSOS REPORTADOS DE LAS VACUNAS CONTRA EL COVID-19.REVISIÓN SISTEMÁTICA
Barra lateral del artículo
Contenido principal del artículo
Resumen
La crisis mundial y económica del año 2020 provocada por la propagación del coronavirus (COVID-19), convirtió a las vacunas en la única esperanza para acabar con la pandemia, debido a que las medidas implementadas no fueron suficientes se hizo necesario la creación de la inmunidad colectiva de la población con la finalidad de lograr reactivar la economía mundial. El objetivo de esta investigación fue describir los efectos adversos de las vacunas contra el COVID-19 e identificar las vacunas que más reacciones adversas generó en la población vacunada. Es un estudio descriptivo, trasversal. La base de datos VAERS reportó 94 % del síndrome de Guillian Barré, 47 % alteraciones cutáneas y ganglios linfáticos. Las reacciones anafilácticas fueron más frecuentes con las vacunas Pfizer-Biotech, Moderna y Astra Zeneca; además de, edema y alergias severas, problemas gastrointestinales, hipo e hipertensión, miocarditis y pericarditis. A pesar de los efectos adversos provocados por las vacunas, la población adquirió inmunidad contra la enfermedad.
##plugins.themes.bootstrap3.displayStats.downloads##
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
Referencias
Abohelwa, M., Elmassry, M., Abdelmalek, J., Payne, D., & Nugent, K. (2021). 2019 Novel Coronavirus Vaccination among Post-graduate Residents and Fellows. Journal of Primary Care & Community Health, 12, 21501327211022978. https://doi.org/10.1177/21501327211022978.
Alhowaymel, F., Abdelmalik, M., Mohammed, A., Mohamaed, M., & Alenezi, A. (2022). Reported Side Effects of COVID-19 Vaccination among Adults in Saudi Arabia: A Cross-Sectional Study. SAGE Open Nursing, 8, 23779608221103208. https://doi.org/10.1177/23779608221103208.
Al Khames, Q., Alkhaffaf, W., Hatem, T., Nassir, K., Batineh, Y., Dahham, A., Shaban, D., Al Khames, L., Agha, M., & Traqchi, M. Safety of COVID-19 vaccines. Journal of Medical Virology, 93(12), 6588-6594. doi: 10.1002/jmv.27214.
Basavaraja, C., Sebastian, J., Mandyam, D., & Sheba, B. (2021) Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India. Therapeutic Advances in Vaccines and Immunotherapy, 9, 1–12. DOI: 10.1177/25151355211055833.
Beatty, A., Peyser, N., Butcher, X., Cocohoba, J., Lin, F., Olgin, J., Pletcher, M., & Marcus GM. (2021). Analysis of COVID-19 vaccine type and adverse effects following vaccination. Journal of American Medical Association Network Open, 4(12), e2140364. doi.org/10.1001/jamanetworkopen.2021.40364.
Bongomin, F., Olum, R., Andia, I., Nakwagala, F., Hassan, K., Nassozi, D., Kaddumukasa, M., Byakika, P., Kiguli, S., & Kirenga, B. (2021). COVID-19 vaccine acceptance among high-risk populations in Uganda. Therapeutic Advances in Infectious Disease, 8, 20499361211024376. DOI: 10.1177/ 20499361211024376.
Bostan, E., Yel, B., Akdogan, N., & Gokoz, O. (2021) New-onset bullous pemphigLi & Lipsond after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin. Dermatologic Therapy, 35 (2): e15241. doi: 10.1111/dth.15241: e15241.
Cairoli E., & Espinosa G. AutLi & Lipsonmmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios. Medicina Clínica (Engl Ed), 157, 247–252. doi: 10.1016/j.medcle.2021.05.003.
Caronna, E., Ballvé, A., Llauradó, A., Gallardo, V., Ariton, D., Lallana, S., López, S., Olivé, M., Quibus, L., Restrepo, J., Rodrigo, M., Vilaseca, A., Hernandez, M., Martinez, M., Alpuente, A., Torres, M., Pujol, R., Alvarez, J., & Pozo, P. (2020). Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia, 40(13):1410-1421. doi: 10.1177/0333102420965157.
Centers for Disease Control (2021) COVID-19 vaccine safety updates. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf.
Centers for Disease Control. (2023). https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html.
Coto, P., Fernández, M., Mir, M., García, B., González, I., Alonso, P., González, M., Gutiérrez, A., Miranda, E., & Martinón, F. (2022). Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature. Clinical and Experimental Dermatology, 47(1), 141-143. doi: 10.1111/ced.14835.
Chakraborty, I., & Maity, P. (2020). COVID-19 outbreak: Migration, effects on society, global environment and prevention. Science of the Total Environment, 728, 138882. https://dLi & Lipson.org/10.1016/j.scitotenv.2020.138882
Chi, W., Li, Y., Huang, H., Chan, T., Chow, S., Su, J., Ferrall, L., Hung, C., & Wu, T. (2022). COVID‑19 vaccine update: vaccine effectiveness, SARS‑CoV‑2 variants, boosters, adverse effects, and immune correlates of protection. Journal of Biomedical Science, 29 (1), 82. doi: 10.1186/s12929-022-00853-8.
Darrigade, A., Théophile, H., Sanchez, P., Milpied, B., Colbert, M., Pedeboscq, S., Pistone, T., Jullié, M., & Seneschal, J. (2021). Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine. Allergy,76(10), 3194-3196. doi: 10.1111/all.14981.
DeRoo, S., Pudalov, N., & Fu, L. (2020). Planning for a COVID-19 vaccination program. Journal of the American Medical Association, 323(24), 2458–2459. https://doi.org/10.1001/jama.2020.8711.
Di Pasquale, A., Bonanni, P., Garçon, N., Stanberry, L., El‐Hodhod, M., & Tavares, F. (2016). Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine, 34(52):6672‐6680. doi: 10.1016/j.vaccine.2016.10.039.
Ekizoglu, E., Gezegen, H., Yalınay, P., Orhan, E., Ertaş, M., & Baykan, B. (2022). The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic. Cephalalgia, 42, (4-5), 366-375. https://doi.org/10.1177/03331024211042390.
Gambichler, T., Hamdani, N., Budde, H., Sieme, M., Skrygan, M., Scholl, L., Dickel, H., Behle, B., Ganjuur, N., Scheel, C., Abu, N., Ocker, L., Stranzenbach, R., Doerler, M., Pfeiffer, L., Becker, J. (2021). Bullous pemphigLi & Lipsond after SARS-CoV-2 vaccination: spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies. British Journal of Dermatology, 186, 728–731. doi: 10.1111/bjd.20890.
Ganga K, Solyar AYand Ganga R, (2021) Massive Cervical Lymphadenopathy Post-COVID-19 vaccination. Ear, Nose & Throat Journal, 103(4), 255-257 Doi: 10.1177/01455613211048984.
Jaiswal, V., Gaurav, N., Dijamco, P., Ishak, A., Dagar, M., Sarfraz, Z., Shama, N., Sarfraz, A., Lnu, K., Mitra, S., Agarwala, P., Naz, S., Song, D., & Jaiswal, A. (2022). Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review. Journal of Primary Care & Community Health, 13, 21501319221074450. Doi: 10.1177/21501319221074450.
Kantarcioglu, B., Iqbal, O., Lewis, J., Charles, A., Carter, B., Meharvan, S., Lievano, F., Ligocki, M., Jeske, W., Adiguzel, C., Gerotziafas, G., & Fareed, J. (2022). An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis, 28, 10760296211056648. https://journals.sagepub.com/doi/full/10.1177/10760296211056648.
Kasperkiewicz, M., & Woodley, D. (2021). Association between vaccination and autLi & Lipsonmmune bullous diseases: a systematic review. Journal of the American Academy of Dermatology, 86, 1160–1164. doi: 10.1016/j.jaad.2021.04.061.
Krishnakumar, H., Gretchel, A., Holland, T., Martinez, M., Hendrix, L., Collins, M., Donate, M., England, M., Kumana, E., Garcia, J., Wilkey, A., Akula, N., Mai, A., & Patel, D. (2022). Understanding Questions and Concerns Regarding COVID-19 and the COVID-19 Vaccine Among Populations Presenting at a COVID-19 Vaccine Clinic Hub: A Qualitative Study. Journal of Primary Care & Community Health, 13, 21501319221118477. DOI: 10.1177/21501319221118477.
Kwok, K., Li, K., Wei, W., Tang, A., Wong, S., & Lee, S. (2021). Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey. International Journal of Nursing Studies, 114, 103854. https:// doi: org/10.1016/j.ijnurstu.2020.103854.
Li, H., & Lipson, J. (2022). New mycosis fungLi & Lipsondes–like lymphomatLi & Lipsond reaction following COVID-19 vaccination: Case report. SAGE Open Medical Case Reports, 10, 2050313X221131859. doi: 10.1177/2050313X221131859.
Li, Y., Chi, W., Su, J., Ferrall, L., Hung, C., & Wu, T. (2020). Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science, 27(1),104. Doi: 10.1186/s12929-020-00695-2.
Li, K., Chen, G., Hou, H., Liao, Q., Chen, J., Bai, H., Lee, S., Wang, C., Li, H., Cheng, L., & Ai, J. (2021).
Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reproductive Biomedicine Online, 42(1):260-267. Doi: 10.1016/j.rbmo.2020.09.020.
Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 7(1),146. https://doi.org/10.1038/s41392-022-00996-y.
Lodato, F., Larocca, A., D' Errico, A. & Cennamo, V. (2021) An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: Coincidence, autoimmunity or drug-related liver injury. Journal of Hepatology, 75 (5), 1254–1256. doi: 10.1016/j.jhep.2021.07.005.
Mayfield, J., Bandi, S., Ganti, L., & Rubero, J. (2021) Anaphylaxis after Moderna COVID-19 vaccine. Therapeutic Advances in Vaccines and Immunotherapy, 9, 25151355211048418. DOI: 10.1177/25151355211048418.
McMahon, D., Amerson, E., Rosenbach, M., Lipoff, J., Moustafa, D., Tyagi, A., Desai, S., French, L., Lim, H., Thiers, B., Hruza, G., Blumenthal, K., Fox, L., & Freeman, E. (2021). Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. Journal of the American Academy of Dermatology, 85(1), 46-55. doi: 10.1016/j.jaad.2021.03.092.
Nawas, G., Zeidan, R., Edwards., & El-Desoky, R. (2022). Barriers to COVID-19 Vaccines and Strategies to Improve Acceptability and Uptake. Journal of Pharmacy Practice,36(4),900–904. https://journals.sagepub.com/doi/abs/10.1177/08971900221081621.
Oguh C, Obiwulu E, Oniwon W, Okekeaji, U., Ugwu, C., Umezinwa, O., & Osuji, C. (2020). Structure and function of COVID‐19 Encode Proteins In The Transcription And Replication Mechanism with Its Preventive Measures and Propose Efficacy Treatments: A Critical Systematic Review. Asian Journal Immunology, 3 (1),145‐159. https://journalaji.com/index.php/AJI/article/view/42.
Pérez, I., Moyano, D., & Ruiz, R. (2021), Bullous pemphigoid and COVID-19 vaccine. Medicina Clínica English Edition), 157(10): e333–4. DOI: 10.1016/j.medcle.2021.05.004.
Qanneta, R. (2023) Radiculopatía lumbar aguda secundaria a infección por virus herpes varicela-zóster, después de la vacuna anti-COVID19 BioNTech/Pfizer en un paciente anciano, Revista Española de Geriatría y Gerontología, 58 (3), 171-172. DOI: 10.1016/j.regg.2023.01.002.
Riad, A., Pokorná, A., Attia, S., Klugarová, J., Koščík, M., & Klugar, M. (2021). Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. Journal of Clinical Medicine, 10(7), 1428. https://doi.org/10. 3390/jcm10071428.
Rodríguez, L., Toro, M., Martínez, M., & Patiño, A. (2022). Menstrual cycle disturbances after COVID-19 vaccination. Women’s Health, 18, 17455057221109375. https://doi.org/10.1177/17455057221109375.
Rosner, C., Genovese, L., Tehrani, B., Atkins, M., Bakhshi, H., Chaudhri, S., Damluji, A., De Lemos, J., Desai, S., Emaminia, A., Flanagan, M., Khera, A., Maghsoudi, A., Mekonnen, G., Muthukumar, A., Saeed, I., Sherwood, M., Sinha, S., O’Connor, C.,… deFilippi, Ch. (2021). Myocarditis temporally associated with COVID-19 vaccination. Circulation, 144, 502–505. doi: 10.1161/CIRCULATIONAHA.121.055891.
Rose, R., Kitchin, R., Apostolopoulou, E., Rickards, L., Blackman, T., Crampton, J., Rossi, U., & Buckley M., (2020). Geographies of the COVID-19 pandemic. Dialogues in Human Geography, 10 (2), 97-106. https://doi.org/10.1177/2043820620936050.
Rudolph, A., Mitchell, J., Barrett, J., Sköld, H., Taavola, H., Erlanson, N., Melgarejo, C., & Yue, Q. (2022). Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge. Therapeutic Advances in Drug Safety, 13, 20420986221118972. DOI: 10.1177/20420986221118972.
Sebastian, J., Ravi, M., & Kumar, T. (2020). COVID-19 vaccine development, trials and tribulations. Indian Journal of Pharmaceutical Education and Research, 54 (3 [Suppl], S457–S463. DOI: 10.5530/ijper.54.3s.144.
Sebastian, J., Mathew, M., Veeranna, S., Madhan, R. (2022) Leukocytoclastic Vasculitis Following COVID-19 Vaccination: A Case Report. Hospital Pharmacy, 57(4), 564-567. doi: 10.1177/00185787211067379.
Sechi, A., Pierobon, E., Pezzolo, E., Germi, L., Trevisan, G., Zardo, D., Riva, G., Mondino, S., & Naldi L. (2022). Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clinical and Experimental Dermatology, 47(2), 437-440. doi: 10.1111/ced.14970.
Sellaturay, P., Nasser, S., Islam, S., Gurugama, P., Ewan, P. (2021). Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clinical and Experimental Allergy, 51 (6), 861–863. doi: 10.1111/cea.13874, 861.
Shimabukuro, T., & Nair, N. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. Journal of the American Medical Association, 325(8), 780–781. doi:10.1001/jama.2021.0600.
Shouli, M., Ahmad, A., Khaila, M., Bilal, M., & Ibrahim, M. (2022). Health Consequences of University Employees Post-COVID-19 Vaccination at Palestinian Universities. SAGE Open Nursing, 8, 23779608221144935. DOI: 10.1177/23779608221144935.
Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., Cardoso, F., Pereira, T., Machado, I., & Lourenço, A. (2021) Perimyocarditis Following COVID-19 Vaccination. Clinical Medicine Insights Cardiology, 15, 11795468211056634. doi: 10.1177/11795468211056634.
Uh, J., Lee, S., Kim, J., Lee, J., Kim, M., & Lee, U. (2022) Cutaneous Small-vessel Vasculitis after ChAdOx1 COVID-19 Vaccination: A Report of Five Cases. International Journal of Lower Extremity Wounds, 21, 2, 193-196 https://doi.org/10.1177/15347346221078734.
Vaccine Adverse Events Reporting System (2023). Datos VAERS. https://vaers.hhs.gov/dataSpanish.html.
Voets, P., Frölke, S., Vogtländer, N., Kaasjager, K. (2021). COVID-19 and dysnatremia: A compari(https://vaers.hhs.gov/aboutSpanish.html), son between COVID-19 and non-COVID-19 respiratory illness. SAGE Open Medicine, 9, 20503121211027778. doi: 10.1177/20503121211027778.
Wan, V., Chen, D., Shiau, C., & Jung, G. (2022). Association between COVID-19 vaccination and bullous pemphigoid - a case series and literature review. SAGE Open Medical Case Reports, 10, 2050313X221131868. doi: 10.1177/2050313X221131868.
World Health Organization. (2018). Drug and Therapeutics Committee Training Course. Assessing and Managing Medicine Safety https://www.who.int/medicines/technical_briefing/tbs/04-PG_Dug-Safety_final-08.pdf?ua=1.
World Health Organization. (2020). WHO Director-General’s opening remarks at the media briefing on COVID-19- 11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–-11-march-2020.
Worldometer. (2023). COVID-19 Coronavirus outbreak. https://www.worldometers.info/coronavirus.
Yap, C., Abulhassan, A., Prabhakar, A., Prabhakar, A., Pal, A., Lim, Y., & Kakodkar, P. (2021) Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Therapeutic Advances in Vaccines and Immunotherapy, 9,1-21. DOI: 10.1177/ 25151355211059791.
Young, J., Mercieca, L., Ceci, M., Pisani, D., Betts, A., & Boffa, M. (2022). A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine. Journal of the European Academy of Dermatology and Venereology, 36 (1), e13–e16. doi: 10.1111/jdv.17676.